Posted by Michael Wonder on 04 Oct 2020
Proposal to transition funded access to dornase alfa to a standard Special Authority
2 October 2020 - PHARMAC is seeking feedback on a proposal to transition the process for obtaining funded access to dornase alfa (Pulmozyme) from the cystic fibrosis panel to a standard Special Authority from 1 December 2020.
The proposal involves the continuation of funding of dornase alpha for eligible patients; the main change would be to the mechanism of application for funding.
In summary, from 1 December 2020 this proposal would result in access to funded dornase alpha transitioning to a standard Special Authority criteria to be listed in Section B and Part II of Section H of the Pharmaceutical Schedule.
